TGD001 not checked

TargED Biopharmaceuticals B.V.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
2 active
2 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Thrombotic Microangiopathies, ITP Immune-Mediated Thrombocytopenia
Main trialPhase 1/2
“This is a Phase 1/2, prospective, adaptive design trial of TGD001 in participants with suspicion or clinical diagnosis of acute immune thrombotic thrombocytopenic purpura (iTTP) episodes and participants with suspicion or clinical diagnosis of an acute Thrombotic Microangiopathy (TMA) episode. The trial is an open-label, dose escalation and expansion basket trial.”In the company’s words, NCT07459114 on ClinicalTrials.gov

Other drugs for Thrombotic Microangiopathies

All 38 drugs for Thrombotic Microangiopathies

Coming up1

Changes1

Last 90 days

Trials2

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 31 May 2028 TGD001 Treatment in Thrombotic Microangiopathies
Phase 1/2Authorised not given A Phase 1b/2a Open-Label Dose-Finding Followed by Randomized, Double-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of TGD001 in Patients with Acute Ischemic Stroke
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow TGD001

Following is part of Solo: you see every change to TGD001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in